These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 21546969)

  • 1. PPAR-γ action: it's all in your head.
    Myers MG; Burant CF
    Nat Med; 2011 May; 17(5):544-5. PubMed ID: 21546969
    [No Abstract]   [Full Text] [Related]  

  • 2. Brain PPAR-γ promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones.
    Lu M; Sarruf DA; Talukdar S; Sharma S; Li P; Bandyopadhyay G; Nalbandian S; Fan W; Gayen JR; Mahata SK; Webster NJ; Schwartz MW; Olefsky JM
    Nat Med; 2011 May; 17(5):618-22. PubMed ID: 21532596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema.
    Gregoire FM; Zhang F; Clarke HJ; Gustafson TA; Sears DD; Favelyukis S; Lenhard J; Rentzeperis D; Clemens LE; Mu Y; Lavan BE
    Mol Endocrinol; 2009 Jul; 23(7):975-88. PubMed ID: 19389808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists on glycemic control, lipid profile and cardiovascular risk.
    Derosa G; Maffioli P
    Curr Mol Pharmacol; 2012 Jun; 5(2):272-81. PubMed ID: 22122457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A role for central nervous system PPAR-γ in the regulation of energy balance.
    Ryan KK; Li B; Grayson BE; Matter EK; Woods SC; Seeley RJ
    Nat Med; 2011 May; 17(5):623-6. PubMed ID: 21532595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PPAR-gamma agonists and their role in type 2 diabetes mellitus management.
    Bermúdez V; Finol F; Parra N; Parra M; Pérez A; Peñaranda L; Vílchez D; Rojas J; Arráiz N; Velasco M
    Am J Ther; 2010; 17(3):274-83. PubMed ID: 20216208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A lesson in moderation: applying pharmacodynamics to clarify the relationship between thiazolidinediones and adverse vascular outcomes in type 2 diabetes.
    Lehmann DF; Lohray BB
    J Clin Pharmacol; 2008 Aug; 48(8):999-1002. PubMed ID: 18650500
    [No Abstract]   [Full Text] [Related]  

  • 8. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
    Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones.
    Hevener AL; Olefsky JM; Reichart D; Nguyen MT; Bandyopadyhay G; Leung HY; Watt MJ; Benner C; Febbraio MA; Nguyen AK; Folian B; Subramaniam S; Gonzalez FJ; Glass CK; Ricote M
    J Clin Invest; 2007 Jun; 117(6):1658-69. PubMed ID: 17525798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Future directions for insulin sensitizers in disease prevention.
    Colca JR
    Curr Opin Investig Drugs; 2007 Sep; 8(9):707-10. PubMed ID: 17729181
    [No Abstract]   [Full Text] [Related]  

  • 11. Releasing the pressure.
    Davenport RJ
    Sci Aging Knowledge Environ; 2005 Jun; 2005(25):nf47. PubMed ID: 15975897
    [No Abstract]   [Full Text] [Related]  

  • 12. Investigational PPAR-gamma agonists for the treatment of Type 2 diabetes.
    Savkur RS; Miller AR
    Expert Opin Investig Drugs; 2006 Jul; 15(7):763-78. PubMed ID: 16787140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of the PPAR-gamma agonist pioglitazone on plasma concentrations of circulating vasoactive factors in type II diabetes mellitus.
    de Boer RA; Martens FM; Kuipers I; Boomsma F; Visseren FL
    J Hum Hypertens; 2010 Jan; 24(1):74-6. PubMed ID: 19847195
    [No Abstract]   [Full Text] [Related]  

  • 14. Stay vigilant: a glitazone (pioglitazone) can hide a glitazar!
    Hillaire-Buys D; Faillie JL; Montastruc JL; Petit P
    Eur J Clin Pharmacol; 2012 Dec; 68(12):1681-3. PubMed ID: 22576730
    [No Abstract]   [Full Text] [Related]  

  • 15. Thiazolidinediones: effects on insulin resistance and the cardiovascular system.
    Quinn CE; Hamilton PK; Lockhart CJ; McVeigh GE
    Br J Pharmacol; 2008 Feb; 153(4):636-45. PubMed ID: 17906687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rosiglitazone and pioglitazone in the treatment of diabetes mellitus.
    Odom J; Williamson B; Carter L
    Am J Health Syst Pharm; 2008 Oct; 65(19):1846-50. PubMed ID: 18796427
    [No Abstract]   [Full Text] [Related]  

  • 17. [Progress in therapy for diabetes mellitus--insulin-resistance ameliorating agents].
    Kaku K
    Nihon Naika Gakkai Zasshi; 2009 Apr; 98(4):742-9. PubMed ID: 19472525
    [No Abstract]   [Full Text] [Related]  

  • 18. Adverse events related to muraglitazar use in diabetes.
    Parra D; Beckey C; Thomas T
    JAMA; 2006 May; 295(17):1997-8; author reply 1998. PubMed ID: 16670403
    [No Abstract]   [Full Text] [Related]  

  • 19. Thiazolidinediones.
    Yki-Järvinen H
    N Engl J Med; 2004 Sep; 351(11):1106-18. PubMed ID: 15356308
    [No Abstract]   [Full Text] [Related]  

  • 20. Divergent effects of peroxisome proliferator-activated receptor-gamma ligands in human and mouse nonalcoholic steatohepatitis.
    Caldwell SH; Argo CK
    Hepatology; 2007 Aug; 46(2):285-7. PubMed ID: 17661403
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.